TEVA241220C16500
- 4.89
- +0.19+4.04%
Teva Pharmaceutical Industries Newsroom
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $28
Teva Pharmaceutical Indus Analyst Ratings
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $28
J.P. Morgan Maintains Teva Pharmaceutical Industries(TEVA.US) With Hold Rating
Teva Pharmaceutical (TEVA) Gets a Hold From J.P. Morgan
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $25
Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $23
UBS Upgrades Teva Pharmaceutical Industries(TEVA.US) to Buy Rating, Maintains Target Price $26
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $25
UBS Downgrades Teva Pharmaceutical Industries(TEVA.US) to Hold Rating, Maintains Target Price $26
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $23
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $25
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $25
Teva Pharmaceutical Indus Analyst Ratings
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $25
Teva Pharmaceutical (TEVA) Receives a Buy From Barclays
Teva Pharmaceutical Indus Analyst Ratings
J.P. Morgan Maintains Teva Pharmaceutical Industries(TEVA.US) With Hold Rating, Raises Target Price to $18
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $26
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22